Drug intelligence / Profile preview

SLAMF7-targeting hemibody

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

The SLAMF7-targeting hemibody is part of a pair of complementary antibody fragments designed to redirect T cells against cancer cells expressing specific antigen combinations. It targets **SLAMF7** and can be used in conjunction with other hemibodies targeting different antigens, such as **CD38**. This approach aims to eliminate dual antigen-positive cancer cells while sparing single antigen-positive bystander cells, reducing off-tumor toxicity. The mechanism involves T cell recruitment and activation against cancer cells, with potential applications in multiple myeloma treatment[1].

Targets

SLAMF7 (Signaling lymphocytic activation molecule family member 7)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on SLAMF7-targeting hemibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLAMF7-targeting hemibody.

Explore the full profile